These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8747313)

  • 1. Adverse reactions associated with skin testing and immunotherapy.
    Lockey RF
    Allergy Proc; 1995; 16(6):293-6. PubMed ID: 8747313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adverse reactions to skin tests and immunotherapy in the practice of Mexican allergologists].
    Larenas Linnemann D; Rodríguez Pérez N; Becerril M
    Rev Alerg Mex; 2008; 55(2):62-70. PubMed ID: 19058483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survey of fatalities from skin testing and immunotherapy 1985-1989.
    Reid MJ; Lockey RF; Turkeltaub PC; Platts-Mills TA
    J Allergy Clin Immunol; 1993 Jul; 92(1 Pt 1):6-15. PubMed ID: 8335856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
    Bukantz SC; Bagg AS; Lockey RF
    Clin Allergy Immunol; 2008; 21():455-68. PubMed ID: 18828523
    [No Abstract]   [Full Text] [Related]  

  • 5. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.
    Bernstein DI; Wanner M; Borish L; Liss GM;
    J Allergy Clin Immunol; 2004 Jun; 113(6):1129-36. PubMed ID: 15208595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety of immunotherapy and skin tests with allergens in children younger than five years].
    Rodríguez Pérez N; Ambriz Moreno Mde J
    Rev Alerg Mex; 2006; 53(2):47-51. PubMed ID: 16884027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-adrenergic blockers, immunotherapy, and skin testing. American Academy of Allergy and Immunology.
    Kaplan AP; Anderson JA; Valentine MD; Lockey RF; Pierson WE; Zweiman B; Kaliner MA; Lichtenstein LM; Lieberman PL; Settipane GA
    J Allergy Clin Immunol; 1989 Jul; 84(1):129-30. PubMed ID: 2569002
    [No Abstract]   [Full Text] [Related]  

  • 8. [Non-fatal systemic reactions caused by immunotherapy and skin tests].
    Rodríguez Pérez N; Ambriz Moreno Mde J; Pizarro Esquivel U
    Rev Alerg Mex; 2002; 49(3):69-73. PubMed ID: 12190001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaphylaxis: still a ghost behind allergen immunotherapy.
    Makatsori M; Calderon MA
    Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):316-22. PubMed ID: 24873937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better documentation through standardized forms: what progress have we made since the 1800s?
    Cox L
    Allergy Asthma Proc; 2004; 25(6):407-22. PubMed ID: 15709452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guidelines to minimize the risk from systemic reactions caused by immunotherapy with allergenic extracts. AAAI Board of Directors. American Academy of Allergy and Immunology.
    J Allergy Clin Immunol; 1994 Apr; 93(4):811-2. PubMed ID: 8163793
    [No Abstract]   [Full Text] [Related]  

  • 12. AAAAI/ACAAI surveillance study of subcutaneous immunotherapy, years 2008-2012: an update on fatal and nonfatal systemic allergic reactions.
    Epstein TG; Liss GM; Murphy-Berendts K; Bernstein DI
    J Allergy Clin Immunol Pract; 2014; 2(2):161-7. PubMed ID: 24607043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter real-world experience with epinephrine 0.5 mg dosing for anaphylaxis with allergen immunotherapy.
    Correa N; Quidwai A; Jeimy S; Rondilla N; White F; Moote W; Kuprowski M; Kim H
    Immunotherapy; 2021 Nov; 13(16):1325-1331. PubMed ID: 34612079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [WHO position paper (summary)--allergen-immunotherapy: therapeutic vaccines for allergic diseases].
    Malling HJ
    Wien Med Wochenschr; 1999; 149(14-15):410-4. PubMed ID: 10584284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allergen immunotherapy: an updated review of safety.
    James C; Bernstein DI
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):55-59. PubMed ID: 27906697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety considerations in providing allergen immunotherapy in the office.
    Mattos JL; Lee S
    Curr Opin Otolaryngol Head Neck Surg; 2016 Jun; 24(3):226-30. PubMed ID: 27092905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do beta-blockers really enhance the risk of anaphylaxis during immunotherapy?
    Lang DM
    Curr Allergy Asthma Rep; 2008 Mar; 8(1):37-44. PubMed ID: 18377773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.
    Wasserman RL; Factor JM; Baker JW; Mansfield LE; Katz Y; Hague AR; Paul MM; Sugerman RW; Lee JO; Lester MR; Mendelson LM; Nacshon L; Levy MB; Goldberg MR; Elizur A
    J Allergy Clin Immunol Pract; 2014; 2(1):91-6. PubMed ID: 24565775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylaxis in the allergy practice.
    Leatherman BD
    Int Forum Allergy Rhinol; 2014 Sep; 4 Suppl 2():S60-5. PubMed ID: 25182358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety.
    Caminati M; Dama AR; Djuric I; Montagni M; Schiappoli M; Ridolo E; Senna G; Canonica GW
    Expert Rev Clin Immunol; 2015 Feb; 11(2):233-45. PubMed ID: 25484197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.